Quantcast
Home > Quotes > REPH

Recro Pharma, Inc. Common Stock (REPH) Quote & Summary Data

REPH 
$6.22
*  
0.19
2.96%
Get REPH Alerts
*Delayed - data as of Mar. 26, 2019  -  Find a broker to begin trading REPH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
8.25
Today's High / Low
$ 6.44 / $ 6.17
Share Volume
851,874
50 Day Avg. Daily Volume
258,839
Previous Close
$ 6.41
52 Week High / Low
$ 13.05 / $ 4.78
Market Cap
136,782,372
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.14

Intraday Chart

Shares Traded

Share Volume:
851,874
50 Day Avg. Daily Volume:
258,839

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.83

Trading Range

The current last sale of $6.22 is 30.13% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 6.44 $ 13.05
 Low: $ 6.17 $ 4.78

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company that operates through two business segments: an Acute Care segment and a revenue-generating contract development and manufacturing, or CDMO segment, through which we operate a revenue generating manufacturing business in Gainesville, Georgia. We believe that we can bring valuable therapeutic options for patients, prescribers and payers, such as our lead product candidate, injectable meloxicam, to the hospital and related acute care markets. We believe we can create value for our shareholders through the development, registration and commercialization of injectable meloxicam and our other pipeline product candidates, as well as through the ongoing contributions of our cash-flow positive CDMO segment. In addition to our pipeline, we continue to evaluate acquisition, out-licensing and in-licensing opportunities.  ... More ...  



Risk Grade

Where does REPH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 6.31
Open Date:
Mar. 26, 2019
Close Price:
$ 6.22
Close Date:
Mar. 26, 2019


Consensus Recommendation

Analyst Info